Re : Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610
| Errataetall: |
CommentOn: Eur Urol Oncol. 2023 Dec;6(6):604-610. - PMID 37005212 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
European urology oncology - 6(2023), 6 vom: 23. Dez., Seite 638-639 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shapiro, Daniel D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 11.01.2024 published: Print-Electronic CommentOn: Eur Urol Oncol. 2023 Dec;6(6):604-610. - PMID 37005212 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.euo.2023.05.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357704827 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357704827 | ||
| 003 | DE-627 | ||
| 005 | 20240114234203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euo.2023.05.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1257.xml |
| 035 | |a (DE-627)NLM357704827 | ||
| 035 | |a (NLM)37268448 | ||
| 035 | |a (PII)S2588-9311(23)00106-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shapiro, Daniel D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Re |b Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 11.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Eur Urol Oncol. 2023 Dec;6(6):604-610. - PMID 37005212 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Karam, Jose A |e verfasserin |4 aut | |
| 700 | 1 | |a Master, Viraj A |e verfasserin |4 aut | |
| 700 | 1 | |a Sexton, Wade J |e verfasserin |4 aut | |
| 700 | 1 | |a Matin, Surena F |e verfasserin |4 aut | |
| 700 | 1 | |a Spiess, Philippe E |e verfasserin |4 aut | |
| 700 | 1 | |a Abel, Edwin Jason |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European urology oncology |d 2018 |g 6(2023), 6 vom: 23. Dez., Seite 638-639 |w (DE-627)NLM285558595 |x 2588-9311 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2023 |g number:6 |g day:23 |g month:12 |g pages:638-639 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.euo.2023.05.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2023 |e 6 |b 23 |c 12 |h 638-639 | ||